Articles tagged with Alzheimer Disease
Researchers have discovered that the harmful amyloid protein in Alzheimer's disease interferes with the cellular process of breaking down proteins, leading to an accumulation of toxic debris. The study reveals a natural mechanism for getting rid of excess amyloid, which may help understand the disease.
Kaj Blennow receives the 2010 ECNP Neuropsychopharmacology Award for his influential contributions to Alzheimer's disease research. His work focuses on developing laboratory measures for clinical diagnosis and therapy monitoring, holding significant implications for drug development and patient care.
A Mayo Clinic study found that mild cognitive impairment was 1.5 times higher in men than women, affecting 16% of individuals aged 70-89 without dementia. The study highlights the need for early diagnosis and therapeutic intervention to address the growing prevalence of dementia.
Researchers from the University of Edinburgh are studying proteins to understand how they clump together with age, a process linked to several conditions. The goal is to design drugs to prevent this aggregation, which causes brain plaques in Alzheimer's and cloudy vision in cataracts.
Researchers have identified gamma-secretase activating protein (GSAP) as a key player in the formation of Alzheimer's disease-plaque beta-amyloid. Gleevec, a cancer drug, shows promise in targeting GSAP and reducing plaque production.
The Lancet Editorial highlights the poor record of Alzheimer's drug trials, citing issues with inaccurate animal models and poor methodology. The best time to treat Alzheimer's may be before memory loss occurs, but this is challenging to model in animals.
Research found that people with insulin resistance and type 2 diabetes are at increased risk of developing brain plaques associated with Alzheimer's disease. The study also discovered a link between abnormal blood sugar control tests and the presence of these plaques.
Early testing and drug development are critical issues in Alzheimer's care, according to Dr. Kenneth S. Kosik, who argues that the medical system is not equipped to address patients' questions about treatment and end-of-life care.
A study by the University of South Florida found that the rheumatoid arthritis signaling protein GM-CSF reduces AD pathology and eliminates memory loss in mice. The researchers suggest that GM-CSF boosts immune cells to remove Alzheimer's plaques, improving memory decline.
A 70-year-old woman presented with confusion and memory loss, leading to a misdiagnosis of Alzheimer's disease. However, treatment with cyclophosphamide infusions and steroids revealed an alternative diagnosis of limbic encephalitis.
Scientists use cutting-edge microscope to measure how brain cells respond to pressure, finding that intermediate form of amyloid-beta peptide stiffens cells the most. This discovery could lead to new ways to screen drugs for Alzheimer's and similar diseases.
A recent study published in The Journal of Neuroscience explains the unique molecular action of memantine, a FDA-approved drug for Alzheimer's disease, that underlies its rare side effects. Memantine improves symptoms by blocking abnormal glutamate activity, sparing synaptic receptors and minimizing harm.
Research from the University of Gothenburg found a link between middle age stress and late-life dementia, especially Alzheimer's disease. Women who reported repeated periods of stress in middle age were 65% more likely to develop dementia.
Researchers have discovered that common soluble proteins can become insoluble and form aggregates as a normal part of aging. The presence of these aggregates may influence both lifespan and neurodegenerative disease progression.
A study found that protein clumps are a normal part of aging and can influence neurodegenerative diseases. The discovery was made using the roundworm <i>C. elegans</i> and found that many common proteins in healthy individuals contribute to these clumps.
Researchers at UCI identified a long-hidden part of the brain called the perforant path, which may help with early diagnosis. The study used ultrahigh-resolution MRI to track water molecules in the brain, confirming the passage weakens gradually with age and deteriorates more quickly due to Alzheimer's disease.
Researchers identified a signature of three biomarkers in cerebrospinal fluid that can correctly classify patients with Alzheimer's disease. The study suggests that these biomarkers can detect the pathogenic process of Alzheimer's disease at an early stage, potentially leading to earlier diagnosis and treatment.
Dr. Andres M. Lozano's phase one trial shows DBS is safe for early-stage Alzheimer's patients, with half showing improved memory capacity. The study suggests a potential treatment approach to extend quality of life for those with the disease.
NYU researchers found that periodontal inflammation increases cognitive dysfunction risk in healthy individuals and those with Alzheimer's. The study linked gum inflammation to brain inflammation, neurodegeneration, and Alzheimer's disease.
Scientists have discovered that neuroglobin protects cells from stroke damage, amyloid toxicity, and lack of oxygen. High levels of neuroglobin in brain neurons may buffer them against the effects of Alzheimer's disease-causing protein accumulation.
DZNE and LMU researchers have identified alpha secretase enzyme ADAM10, which cleaves amyloid precursor protein without forming beta-amyloid plaques. This discovery opens up new possibilities for diagnosing and preventing Alzheimer's disease.
Researchers found that a gaseous molecule called nitric oxide can trigger brain cell death in neurodegenerative diseases. The study discovered a new molecular pathway that leads to cellular suicide, offering new potential for diagnosis and treatment.
Researchers at MIT discovered a link between SIRT1 gene and amyloid plaques in Alzheimer's patients, finding that SIRT1 controls production of devastating protein fragments. Overproduction of SIRT1 in mice with Alzheimer's symptoms improved learning and memory deficits, while deletion exacerbated them.
Fruit fly males with reduced Alzheimer's disease protein activity showed impairments in learning and memory as they aged. Researchers prevented age-related deficits by treating the flies with drugs like lithium or genetic manipulations that reduced nerve-cell signaling.
Researchers found that people with APOE ε4/ε4 gene type have differently shaped brain protein deposits compared to those with the neutral risk gene type. The findings suggest that different shapes might respond differently to treatments, supporting a hypothesis that APOE genotype changes amyloid structure.
Researchers find vascular disease in the brain causes dementia in diabetics, while Alzheimer's-related plaque is more common in nondiabetics. A new blood test may be more accurate for predicting Alzheimer's disease in nondiabetics.
A recent study published in Archives of Neurology found that consuming more vitamin E through the diet is associated with a lower risk of dementia and Alzheimer's disease. The researchers analyzed data from over 5,400 participants and found that those who consumed the most vitamin E had a 25% lower risk of developing dementia.
A Mayo Clinic study found that individuals with mild cognitive impairment (MCI) who experience depression or apathy are at a higher risk of developing dementia. Researchers identified biomarkers for MCI progression, highlighting the importance of evaluating patients for neuropsychiatric symptoms.
A new study from the University of Michigan found significant variations in emotional reactions among black, white, and Hispanic caregivers of Alzheimer's patients. The research suggests that racial and ethnic differences play a crucial role in shaping their grieving experiences.
A recent study published in Neurology found that individuals with larger heads who have Alzheimer's disease tend to exhibit better memory and cognitive skills. The research suggests that brain reserve, or the individual capacity to withstand changes in the brain, plays a crucial role in protecting against Alzheimer's symptoms.
Researchers at UC Davis have found a distinctive pattern of brain imaging and biomarker deviations that may indicate an early warning sign of Alzheimer's disease. The study, published in Neurobiology of Aging, analyzed data from over 800 older adults and identified three subgroups with distinct imaging and laboratory measures.
A University of Oklahoma researcher is developing a novel therapy for Alzheimer's disease by targeting the toxic plaque in the brain. The therapy uses biopharmaceutical proteases that can degrade thousands of plaque molecules, potentially delivering a catalytic benefit even if only small amounts pass through the cell barrier.
A study found that depressive symptoms barely increase before diagnosis and remain stable after diagnosis in patients with Alzheimer's disease. The results suggest depression may be a contributing factor to the disease rather than an early sign.
A study found that higher concentrations of clusterin protein in plasma are associated with the development and severity of Alzheimer's disease. Clusterin levels were also linked to rapid cognitive decline, brain atrophy, and increased amyloid-beta accumulation.
A new study published in Neurology shows that having depression may increase the risk of developing dementia later in life by nearly 70%. The study examined data from over 900 people with an average age of 79 and found that those with depressive symptoms were more likely to develop dementia, particularly Alzheimer's disease.
A new study has identified two tests - episodic memory test and PET brain scan - that can accurately predict the development of Alzheimer's disease. These tests are nearly 12 times more effective than others in predicting disease progression.
A University of Kentucky study found changes in white matter connections in high-risk Alzheimer's patients before symptoms manifest. The research used MRI to assess microstructural integrity of axons and myelin in the brains of high- and low-risk groups.
Researchers have made significant discoveries in the fields of atherosclerosis and Alzheimer's disease, revealing new insights into the role of neutrophils and hyperploidy. A study found that neutrophils contribute to atherosclerosis, while another discovered that hyperploid neurons are more prone to cell death in Alzheimer's disease.
Scientists discovered characteristic amyloid plaques in human retinas and developed a noninvasive optical imaging technique to detect retinal plaques in live laboratory mice. The study suggests the possibility of early noninvasive diagnosis and monitoring of Alzheimer's disease through retinal imaging.
Researchers found that carvedilol can lessen the degenerative impact of Alzheimer's disease and promote healthy memory functions in mice. The study suggests that certain antihypertensive drugs already available to the public may independently influence memory functions.
Researchers developed a new radiotracer, florbetapir F18, to distinguish between Alzheimer's disease patients and healthy volunteers on brain scans. The compound has a longer half-life than previous options, allowing for more widespread use and potential applications in diagnosing dementia and tracking disease progression.
A study by Rensselaer Polytechnic Institute professor Peter M. Tessier has found that an organic compound in red wine, resveratrol, can neutralize the toxic effects of proteins linked to Alzheimer's disease. The research provides insights into the structural differences between toxic and benign peptide arrangements.
A study found that genetic variants and neuroimaging measures are associated with Alzheimer's disease risk, providing new insights into the condition's mechanisms. The research identified three new genetic loci linked to Alzheimer's disease, as well as two new targets for future study.
A study by UT Southwestern Medical Center researchers found that APOE4 interferes with brain cell recycling of surface receptors, increasing Alzheimer's disease risk. The harmful molecule prevents the Reelin-binding receptor from being recycled back to the surface.
Mutations in the presenilin 1 gene disrupt cellular protein-recycling, killing nerve cells and leading to neuronal loss. Alternative pathways can be targeted for therapies aimed at repairing toxic protein elimination mechanisms.
Researchers at the University of Granada have created a new system for early diagnosis of Alzheimer's disease using processed images. The system achieved an impressive 90% success rate in identifying patients with Alzheimer's disease.
Research suggests that abnormalities in blood clot formation contribute to AD pathogenesis. A new therapeutic strategy aims to slow cognitive decline by targeting altered blood clotting caused by amyloid peptide.
Researchers found that cholinesterase inhibitors improved executive function, visual attention, and simulated driving task performance in patients with mild Alzheimer's disease. The study suggests that these medications may help improve driving abilities in AD patients.
Chester A. Mathis receives SNM's 2010 Aebersold Award for his groundbreaking work on early detection in Alzheimer's disease using positron emission tomography (PET) imaging techniques. This recognition acknowledges the significant contributions of Dr. Mathis to advancing molecular imaging and nuclear medicine.
Researchers at UTHealth and UH will use nanotechnology and new imaging techniques to study the effects of Amyloid-Beta on the brain. The goal is to create new intravenous delivery mechanisms for gamma secretase modulators, which could potentially protect against Alzheimer's development.
Dr. Castellani's work challenged the traditional view of Alzheimer's disease pathogenesis and highlighted the beneficial effects of amyloid formation. He received the award for his outstanding contribution to understanding the neuroprotective role of amyloid-β protein precursor and amyloid-β.
Researchers at Tufts University School of Medicine identified a protein that regulates the accumulation of an enzyme linked to Alzheimer's disease. Increasing levels of this protein may prevent the progression of the neurodegenerative disorder.
A team of researchers has discovered that amyloid-β protein accumulates in the eyes of people with Down syndrome, leading to distinctive cataracts. The findings may lead to an innovative eye test for early detection of Alzheimer's pathology in both disorders.
Researchers from the University of the Basque Country have identified a new mechanism for amyloid peptide-induced neuronal death. By blocking specific receptors, neurons can be protected from lethal effects, paving the way for novel therapies to slow Alzheimer's progression.
Researchers successfully convert glial cells into two main classes of cortical neurons, paving the way for a potential therapy for neurodegenerative diseases. The discovery uses selective transduction of specific proteins to regulate DNA transcription and yields functioning synapses.
The Alzheimer's Solution proposes community centers for dementia care, addressing the need for novel solutions to address this disease. The centers would provide programs of care, treatment, and prevention, taking a family-oriented and personalized approach.
A comprehensive study identifies significant cognitive and anatomic differences in Alzheimer's disease patients with and without the APOE ε4 gene, affecting memory, attention, language, and executive function. The findings have important implications for early diagnosis, treatment, and personalized medicine approaches.
Researchers at Intermountain Medical Center found ablation treatment significantly reduces risk of Alzheimer's disease and stroke. Atrial fibrillation patients treated with catheter ablation have lower risk of dementia and mortality compared to untreated patients.
Researchers from Boston University School of Medicine found that music enhances recognition memory for Alzheimer's patients, but not healthy older adults. The study suggests that understanding musical processing and memory may lead to effective therapies for this prevalent disease.
A study identified two genetic variations linked to Alzheimer's disease, but these did not enhance the ability to predict AD risk. The findings provide insights into pathophysiological mechanisms of AD.